Catalyst
Slingshot members are tracking this event:
Palatin Technologies Presents Bremelanotide Alcohol Interaction Study at International Society for the Study of Women’s Sexual Health Annual Meeting
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PTN | Community voting in process | |||||
Additional Information
Top-line results of Palatin’s ongoing Phase 3 clinical trials of bremelanotide for female sexual dysfunction are on target for release in the third quarter of calendar year 2016. Assuming the Phase 3 trials are successful, Palatin will file a New Drug Application (NDA) with the FDA in the first half of calendar year 2017.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 26, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Bremelanotide
